The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
Open accessAbstract
Background There is a substantial and unmet clinical need for pharmacological treatment of cannabis use disorders. Cannabidiol (CBD) could offer a novel treatment but it is unclear which doses might be effective or safe. Methods Participants meeting DSM-5 cannabis use disorder criteria were allocated to four-week treatment with oral CBD at 200mg, 400mg, 800mg or placebo during a cessation attempt using a double-blinded block randomisation sequence. All received a brief psychological intervention of motivational interviewing. An adaptive Bayesian dose-finding design was used to identify effective/ineffective doses at a priori interim and final analysis stages. The primary objective was to identify the Most Effective Dose (MED) of CBD for reducing cannabis use. The primary endpoint was lower urinary THC-COOH:creatinine concentrations and/or increased days per week abstinent from cannabis during treatment, evidenced by posterior probabilities exceeding Pr=0.9 for CBD versus placebo. All analyses were intention-to-treat. Outcomes Participants were initially randomised to placebo, 200mg, 400mg and 800mg CBD (n=48; 1:1:1:1). At interim analysis 200mg CBD was eliminated from the trial as an ineffective dose. Randomisation continued to 400mg CBD, 800mg CBD, and placebo (n=34; 1:1:1). At final analysis, both 400mg CBD and 800mg CBD exceeded primary endpoint criteria (Pr=0.9) for both primary outcomes: urinary THC-COOH:creatinine (Pr(400mg=MED | Data)=0.9995; Pr(800mg=MED | Data)=0.9965), days per week abstinent from cannabis (Pr(400mg=MED | Data)=0.9966; Pr(800mg=MED | Data)=0.9247). Compared to placebo, 400mg CBD decreased THC-COOH:creatinine concentrations by -94.21 ng/ml (95% Interval Estimate= -161.83, -35.56) and increased abstinence from cannabis by 0.48 days per week (95% Interval Estimate=0.15, 0.82). Compared to placebo, 800mg CBD decreased THC-COOH:creatinine concentrations by -72.02 ng/ml (95% Interval Estimate= -135.47, -19.52) and increased abstinence from cannabis by 0.27 days per week (95% Interval Estimate= -0.09, 0.64). CBD was well tolerated with no severe adverse events and 94% completed treatment. Interpretation In the first randomised clinical trial of CBD for cannabis use disorder, 400mg and 800mg CBD were safe and more effective than placebo at reducing cannabis use. Trial registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000361-36/GB
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039
Psychosocial interventions for cannabis use disorder
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005336.pub4 · Cited by 282
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4291-09.2009 · Cited by 210
Morgan, C. J., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.58 · Cited by 196
Self-citationCrippa, J. A. S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12018 · Cited by 101
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Research works printed but not linked: 29
- Curran, 2016, Keep off the grass? Cannabis, cognition and addiction, Nat Rev Neurosci, 17, 293, 10.1038/nrn.2016.28 · DOI · Paper page
- Degenhardt, 2018, The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Psychiatry, 5, 987, 10.1016/S2215-0366(18)30337-7 · DOI · Paper page
- Freeman, 2019, Increasing potency and price of cannabis in Europe, 2006–16, Addiction, 114, 1015, 10.1111/add.14525 · DOI
- Chandra, 2019, New trends in cannabis potency in USA and Europe during the last decade (2008–2017), Eur Arch Psychiatry Clin Neurosci, 269, 5, 10.1007/s00406-019-00983-5 · DOI · Paper page
- Freeman, 2015, Examining the profile of high-potency cannabis and its association with severity of cannabis dependence, Psychol Med, 45, 3181, 10.1017/S0033291715001178 · DOI · Paper page
- Meier, 2017, Associations between butane hash oil use and cannabis-related problems, Drug Alcohol Depend, 179, 25, 10.1016/j.drugalcdep.2017.06.015 · DOI
- Freeman, 2018, Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands, Psychol Med, 48, 2346, 10.1017/S0033291717003877 · DOI
- Di Forti, 2019, The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study, Lancet Psychiatry, 6, 427, 10.1016/S2215-0366(19)30048-3 · DOI · Paper page
- Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, Br J Pharmacol, 134, 845, 10.1038/sj.bjp.0704327 · DOI · Paper page
- Freeman, 2019, Medicinal use of cannabis based products and cannabinoids, BMJ, 365
- Freeman, 2019, How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review, Neurosci Biobehav Rev, 107, 696, 10.1016/j.neubiorev.2019.09.036 · DOI · Paper page
- Hindocha, 2018, Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal, Addiction, 113, 1696, 10.1111/add.14243 · DOI
- Hurd, 2019, Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial, Am J Psychiatry, 176, 911, 10.1176/appi.ajp.2019.18101191 · DOI · Paper page
- Morgan, 2013, Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings, Addict Behav, 38, 2433, 10.1016/j.addbeh.2013.03.011 · DOI · Paper page
- Chesney, 2020, Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials, Neuropsychopharmacology, 10.1038/s41386-020-0667-2 · DOI · Paper page
- Shannon, 2015, Cannabidiol oil for decreasing addictive use of marijuana: a case report, Integr Med (Encinitas), 14, 31
- Solowij, 2018, Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial, Cannabis Cannabinoid Res, 3, 21, 10.1089/can.2017.0043 · DOI
- Allsop, 2015, Cannabinoid replacement therapy (CRT): nabiximols (sativex) as a novel treatment for cannabis withdrawal, Clin Pharmacol Ther, 97, 571, 10.1002/cpt.109 · DOI
- Lintzeris, 2019, Nabiximols for the treatment of cannabis dependence: a randomized clinical trial, JAMA Intern Med, 179, 1242, 10.1001/jamainternmed.2019.1993 · DOI
- Trigo, 2018, Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial, PLoS One, 13, 10.1371/journal.pone.0190768 · DOI
- Zuardi, 2017, Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life, Front Pharmacol, 8, 259, 10.3389/fphar.2017.00259 · DOI · Paper page
- Campos, 2008, Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats, Psychopharmacology (Berl), 199, 223, 10.1007/s00213-008-1168-x · DOI · Paper page
- Cunha, 1980, Chronic administration of cannabidiol to healthy volunteers and epileptic patients, Pharmacology, 21, 175, 10.1159/000137430 · DOI · Paper page
- Kotz, 2013, Predictive validity of the Motivation To Stop Scale (MTSS): a single-item measure of motivation to stop smoking, Drug Alcohol Depend, 128, 15, 10.1016/j.drugalcdep.2012.07.012 · DOI · Paper page
- Hindocha, 2016, No smoke without tobacco: a global overview of cannabis and tobacco routes of administration and their association with intention to quit, Front Psychiatry, 7, 104, 10.3389/fpsyt.2016.00104 · DOI · Paper page
- Taylor, 2018, A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects, CNS Drugs, 32, 1053, 10.1007/s40263-018-0578-5 · DOI · Paper page
- Curran, 2018, Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects?, Psychol Med, 49, 1574, 10.1017/S003329171800226X · DOI
- Allsop, 2011, The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress, Drug Alcohol Depend, 119, 123, 10.1016/j.drugalcdep.2011.06.003 · DOI · Paper page
- Beck, 1961, An inventory for measuring depression, Arch Gen Psychiatry, 4, 561, 10.1001/archpsyc.1961.01710120031004 · DOI · Paper page
Cited by
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Self-citationFischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., Brink, W. V. D., et al. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103381 · Cited by 236
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
Metadata
- Authors
- Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., Bloomfield, M. A. P., O'Ryan, D., Kinghorn, J., Morgan, C. J. A., Mofeez, A., & Curran, H. V.
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 7
- Issue
- 10
- Pages
- 865-874
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W3046002454
- Cited by
- 203
- References
- 10
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Medical Research Council (MR/K015524/1)
- Society for the Study of Addiction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. https://app.cochat.ai/papers/10.1016/s2215-0366(20)30290-x
- The paper
- Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., Bloomfield, M. A. P., O'Ryan, D., Kinghorn, J., Morgan, C. J. A., Mofeez, A., & Curran, H. V. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(20)30290-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.